key: cord-0709123-ozqqld4a
authors: Al-Abdi, Sameer; Al-Aamri, Maryam
title: G6PD deficiency in COVID-19 pandemic: “a ghost in the ghost”
date: 2020-04-18
journal: Hematol Oncol Stem Cell Ther
DOI: 10.1016/j.hemonc.2020.04.002
sha: 903beebe2ed1ac5f5c0b8e1cdc663fbcb08e366c
doc_id: 709123
cord_uid: ozqqld4a

nan

deficiency [4, 5] . Another reason for this absence could be that G6PD deficiency in the countries most affected by COVID-19 is rare and/or of the mild type. In Hubei province in China, the origin of COVID-19, the incidence of G6PD deficiency is only 0.098% and about 50% of these are due to WHO class III mild type [6] . We are anticipating that a report outlining the association between G6PD deficiency and COVID-19 may come from countries in which severe G6PD deficiency is very common. Such report is needed urgently. In Saudi Arabia, G6PD deficiency is not included in the list of diseases requiring additional precautionary measures to reduce risk of COVID-19. As per the traditional notion, "absence of evidence is not evidence of absence", it may be prudent to include G6PD deficiency in this list.

G6PD deficiency can be a challenge during the COVID-19 pandemic. The above-cited ex vivo study has found that α-lipoic acid can attenuate the vulnerability of G6PD-deficient cells [3] .

Thus, α-lipoic acid has been proposed as a treatment option for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 [4] .

Hydroxychloroquine has been proposed as a treatment for COVID-19 and clinical trials have been started evaluating this proposal. Hydroxychloroquine has oxidative properties that could decrease glutathione levels and may cause severe hemolysis in G6PD-deficient patients [5] . If hydroxychloroquine is found to be the silver bullet for COVID-19, then this may be a big challenge in treating COVID-19 in G6PD-deficient patients. Accordingly, it is prudent to use additional precautionary measures to prevent COVID-19 from reaching G6PD-deficient individuals.

The authors declare no conflicts of interest.

G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map

Lower reference limits of quantitative cord glucose-6-phosphate dehydrogenase estimated from healthy term neonates according to the clinical and laboratory standards institute guidelines: a cross sectional retrospective study

Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection

Potential interventions for novel coronavirus in China: A systematic review

Dietary restrictions for people with glucose-6-phosphate dehydrogenase deficiency

Chinese newborn screening for the incidence of G6PD deficiency and variant of G6PD gene from